Guidance From Dr. Rakesh Jain on Treating TD During the Pandemic
In this video, Psych Congress Steering Committee member Rakesh Jain, MD, MPH, offers guidance on the proper treatment of tardive dyskinesia (TD) during the COVID-19 pandemic.
Dr. Jain is Clinical Professor, Department of Psychiatry, Texas Tech University School of Medicine, Austin.
Hello, everybody. This is Rakesh Jain, a psychiatrist and a proud member of the Psych Congress Steering Committee. I sincerely hope, during these difficult times with the pandemic occurring, that you, your family, and your patients are doing well.
I'm looking forward to this opportunity to have a deep conversation with you about the many challenges our patients with tardive dyskinesia face today. Despite these challenges, there might be opportunities for us to serve them well. This particular conversation, hopefully, will drive home a few points that could help all of us serve our patients better. Let's have that conversation.
The first thing we should remember is that tardive dyskinesia has been with us for a very long time, in fact for decades, in fact pretty much the entire time we have had antipsychotics since the 1950s. It's also appropriate to remember that for several decades, we did put tardive dyskinesia on the back burner. We didn't think about it too much.
That situation did change in the last three 3 years or so, when we obtained some very effective FDA‑approved treatments. My big worry is — and you perhaps share this with me — that this pandemic that we're facing may push tardive back to its original place of ...
More on: www.psychcongress.com